Literature DB >> 25826586

Genotypes and phenotypes in cystic fibrosis and cystic fibrosis transmembrane regulator-related disorders.

Cristina Bombieri1, Manuela Seia2, Carlo Castellani3.   

Abstract

Cystic fibrosis (CF) is characterized by remarkable variability in severity, rate of disease progression, and organ involvement. In spite of the considerable amount of data collected on the relationship between genotype and phenotype in CF, this is still a challenging matter of debate. Barriers to the interpretation of this connection are the large number of mutations in the CF transmembrane regulator (CFTR) gene, the difficulties in attributing several of them to a specific mode of dysfunction, and a limited number of the almost 2,000 mutations so far detected, which have been clinically annotated. In addition to that, the heterogeneity of clinical manifestations in individuals with the same CFTR genotypes indicates that disease severity is modulated by other genes and by environmental factors, of which the most relevant is possibly treatment in its aspects of appropriateness, early start in life, and adherence. The phenotype variability extends to conditions, named CFTR-related disorders, which are connected with CFTR dysfunction, but do not satisfy diagnostic criteria for CF. The current level of knowledge does not allow use of the CFTR genotype to predict individual outcome and cannot be used as an indicator of CF prognosis. This might change with the development of treatments targeting specific mutations and possibly capable of changing the natural history of the disease. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25826586     DOI: 10.1055/s-0035-1547318

Source DB:  PubMed          Journal:  Semin Respir Crit Care Med        ISSN: 1069-3424            Impact factor:   3.119


  16 in total

Review 1.  Cystic fibrosis: a clinical view.

Authors:  Carlo Castellani; Baroukh M Assael
Journal:  Cell Mol Life Sci       Date:  2016-10-05       Impact factor: 9.261

2.  Functional Assays Are Essential for Interpretation of Missense Variants Associated with Variable Expressivity.

Authors:  Karen S Raraigh; Sangwoo T Han; Emily Davis; Taylor A Evans; Matthew J Pellicore; Allison F McCague; Anya T Joynt; Zhongzhou Lu; Melis Atalar; Neeraj Sharma; Molly B Sheridan; Patrick R Sosnay; Garry R Cutting
Journal:  Am J Hum Genet       Date:  2018-05-24       Impact factor: 11.025

3.  IL8 gene as modifier of cystic fibrosis: unraveling the factors which influence clinical variability.

Authors:  Larissa Lazzarini Furlan; Fernando Augusto Lima Marson; José Dirceu Ribeiro; Carmen Sílvia Bertuzzo; João Batista Salomão Junior; Dorotéia Rossi Silva Souza
Journal:  Hum Genet       Date:  2016-05-21       Impact factor: 4.132

4.  Newborn screening for cystic fibrosis: Role of primary care providers in caring for infants with positive screening results.

Authors:  June C Carroll; Robin Z Hayeems; Fiona A Miller; Carolyn J Barg; Yvonne Bombard; Pranesh Chakraborty; Beth K Potter; Jessica Peace Bytautas; Karen Tam; Louise Taylor; Elizabeth Kerr; Christine Davies; Jennifer Milburn; Felix Ratjen; Astrid Guttmann
Journal:  Can Fam Physician       Date:  2021-06       Impact factor: 3.275

Review 5.  Treatment of Pulmonary Disease of Cystic Fibrosis: A Comprehensive Review.

Authors:  Rosa María Girón Moreno; Marta García-Clemente; Layla Diab-Cáceres; Adrián Martínez-Vergara; Miguel Ángel Martínez-García; Rosa Mar Gómez-Punter
Journal:  Antibiotics (Basel)       Date:  2021-04-23

6.  Predictors of sinonasal disease onset, progression, and severity in pediatric cystic fibrosis patients.

Authors:  Michael S Weinstock; Amber D Shaffer; Amanda L Stapleton
Journal:  Am J Otolaryngol       Date:  2021-03-31       Impact factor: 2.873

7.  p.G970D is the most frequent CFTR mutation in Chinese patients with cystic fibrosis.

Authors:  Xinlun Tian; Yaping Liu; Jun Yang; Han Wang; Tao Liu; Wenbing Xu; Xue Li; Yuanjue Zhu; Kai-Feng Xu; Xue Zhang
Journal:  Hum Genome Var       Date:  2016-01-07

8.  Long Non-coding RNA BGas Regulates the Cystic Fibrosis Transmembrane Conductance Regulator.

Authors:  Sheena M Saayman; Amanda Ackley; Jon Burdach; Matthew Clemson; Dieter C Gruenert; Kiyoshi Tachikawa; Pad Chivukula; Marc S Weinberg; Kevin V Morris
Journal:  Mol Ther       Date:  2016-05-30       Impact factor: 11.454

9.  A Genotypic-Oriented View of CFTR Genetics Highlights Specific Mutational Patterns Underlying Clinical Macrocategories of Cystic Fibrosis.

Authors:  Marco Lucarelli; Sabina Maria Bruno; Silvia Pierandrei; Giampiero Ferraguti; Antonella Stamato; Fabiana Narzi; Annalisa Amato; Giuseppe Cimino; Serenella Bertasi; Serena Quattrucci; Roberto Strom
Journal:  Mol Med       Date:  2015-04-21       Impact factor: 6.354

Review 10.  The Impact of Secondhand Smoke Exposure on Children with Cystic Fibrosis: A Review.

Authors:  Benjamin T Kopp; Juan Antonio Ortega-García; S Christy Sadreameli; Jack Wellmerling; Estelle Cormet-Boyaka; Rohan Thompson; Sharon McGrath-Morrow; Judith A Groner
Journal:  Int J Environ Res Public Health       Date:  2016-10-12       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.